166 related articles for article (PubMed ID: 37743239)
21. Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
Mulligan SP; Opat S; Cheah CY; Kuss B; Hertzberg M; Marlton P; Poplar S; Puig A; McGeachie M; Weinkove R; Tam CS
Leuk Lymphoma; 2023 Feb; 64(2):312-318. PubMed ID: 36423351
[TBL] [Abstract][Full Text] [Related]
22. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Chanan-Khan AA; Coutre SE; Davis RS; Eradat H; Fletcher CD; Gaballa S; Ghobadi A; Hamid MS; Hernandez-Ilizaliturri F; Hill B; Kaesberg P; Kamdar M; Kaplan LD; Khan N; Kipps TJ; Ma S; Mato A; Mosse C; Schuster S; Siddiqi T; Stephens DM; Ujjani C; Wagner-Johnston N; Woyach JA; Ye JC; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2022 Jun; 20(6):622-634. PubMed ID: 35714675
[TBL] [Abstract][Full Text] [Related]
23. Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?
Smith CIE; Zain R; Österborg A; Palma M; Buggert M; Bergman P; Bryceson Y
Scand J Immunol; 2022 Apr; 95(4):e13153. PubMed ID: 35244285
[TBL] [Abstract][Full Text] [Related]
24. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Danilov AV; Persky DO
Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
Raa DGT; van der Straten L; van Gelder M; Kersting S; Levin MD; Mous R; van der Straaten HM; Nijziel MR; van der Spek E; Posthuma EFM; Visser HPJ; van der Klift M; de Heer K; Bellido M; Doorduijn JK; Bruns AHW; Raijmakers RAP; Kater AP;
Leuk Lymphoma; 2022 Oct; 63(10):2276-2289. PubMed ID: 35737364
[TBL] [Abstract][Full Text] [Related]
26. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
27. Screening and monitoring of the BTK
Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Mato AR; Roeker LE; Lamanna N; Allan JN; Leslie L; Pagel JM; Patel K; Osterborg A; Wojenski D; Kamdar M; Huntington SF; Davids MS; Brown JR; Antic D; Jacobs R; Ahn IE; Pu J; Isaac KM; Barr PM; Ujjani CS; Geyer MB; Berman E; Zelenetz AD; Malakhov N; Furman RR; Koropsak M; Bailey N; Hanson L; Perini GF; Ma S; Ryan CE; Wiestner A; Portell CA; Shadman M; Chong EA; Brander DM; Sundaram S; Seddon AN; Seymour E; Patel M; Martinez-Calle N; Munir T; Walewska R; Broom A; Walter H; El-Sharkawi D; Parry H; Wilson MR; Patten PEM; Hernández-Rivas JÁ; Miras F; Fernández Escalada N; Ghione P; Nabhan C; Lebowitz S; Bhavsar E; López-Jiménez J; Naya D; Garcia-Marco JA; Skånland SS; Cordoba R; Eyre TA
Blood; 2020 Sep; 136(10):1134-1143. PubMed ID: 32688395
[TBL] [Abstract][Full Text] [Related]
29. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.
Awan FT; Addison D; Alfraih F; Baratta SJ; Campos RN; Cugliari MS; Goh YT; Ionin VA; Mundnich S; Sverdlov AL; Tam C; Ysebaert L
Blood Adv; 2022 Sep; 6(18):5516-5525. PubMed ID: 35790105
[TBL] [Abstract][Full Text] [Related]
30. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
31. Management of chronic lymphocytic leukemia.
Stilgenbauer S; Furman RR; Zent CS
Am Soc Clin Oncol Educ Book; 2015; ():164-75. PubMed ID: 25993154
[TBL] [Abstract][Full Text] [Related]
32. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
33. From gating to computational flow cytometry: Exploiting artificial intelligence for MRD diagnostics.
Riva G; Luppi M; Tagliafico E
Br J Haematol; 2023 Aug; 202(4):715-717. PubMed ID: 37092558
[TBL] [Abstract][Full Text] [Related]
34. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Easaw S; Ezzati S; Coombs CC
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):697-704. PubMed ID: 37544810
[TBL] [Abstract][Full Text] [Related]
35. Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.
Wiedmeier-Nutor J; Leis J
Curr Treat Options Oncol; 2022 Jun; 23(6):904-919. PubMed ID: 35435617
[TBL] [Abstract][Full Text] [Related]
36. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Nakhoda S; Vistarop A; Wang YL
Br J Haematol; 2023 Jan; 200(2):137-149. PubMed ID: 36029036
[TBL] [Abstract][Full Text] [Related]
37. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Hallek M; Cheson BD; Catovsky D; Caligaris-Cappio F; Dighiero G; Döhner H; Hillmen P; Keating M; Montserrat E; Chiorazzi N; Stilgenbauer S; Rai KR; Byrd JC; Eichhorst B; O'Brien S; Robak T; Seymour JF; Kipps TJ
Blood; 2018 Jun; 131(25):2745-2760. PubMed ID: 29540348
[TBL] [Abstract][Full Text] [Related]
38. The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
Ujjani C; Shadman M; Lynch RC; Tu B; Stevenson PA; Grainger C; Zhu H; Hill JA; Huang ML; Nielsen L; Poh C; Sorensen T; Gopal AK; Warren EH; Till BG; Lee S; Gausman D; Smith SD; Gooley T; Greninger A
Br J Haematol; 2022 May; 197(3):306-309. PubMed ID: 35149986
[TBL] [Abstract][Full Text] [Related]
39. Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.
Campbell A; Teh B; Mulligan S; Ross DM; Weinkove R; Gilroy N; Gangatharan S; Prince HM; Szer J; Trotman J; Lane S; Dickinson M; Quach H; Enjeti AK; Ku M; Gregory G; Hapgood G; Ho PJ; Cochrane T; Cheah C; Greenwood M; Latimer M; Berkahn L; Wight J; Armytage T; Diamond P; Tam CS; Hamad N
Intern Med J; 2024 Feb; 54(2):328-336. PubMed ID: 38146232
[TBL] [Abstract][Full Text] [Related]
40. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
